The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023. We ask healthcare professionals to review…
The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023. We ask healthcare professionals to review…
This content is sourced from MHRA and reproduced for clinical reference. ClinicalIQ does not alter source content.
Get weekly clinical updates — guidelines, trials, MHRA alerts — delivered to your inbox. Free for verified HCPs.
By registering you confirm you are a healthcare professional. No spam. Unsubscribe anytime.